Logo

Isis Licenses Antisense Tools to Merck

Feb 21, 2002

NEW YORK, Feb. 21 - Isis Pharmaceuticals has struck a deal with Merck to provide the pharmaceutical giant with antisense tools for drug-target validation, the company said on Thursday.

 

Under the agreement, Merck will use Isis antisense techniques to probe the biological function of genes of interest, and ascertain their utility as potential drug targets.

 

The two companies have other collaborations: Isis licensed a type 2 diabetes drug candidate to Merck in 2001, and the two firms are partnering in a hepatitis C drug discovery program.

Breaking News
The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.